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Abstract
Background: Migraine, tension-type headache (TTH) and medication-overuse headache (MOH) are disabling
lifelong illnesses. The Eurolight project, a partnership activity within the Global Campaign against Headache,
assessed the impact of headache disorders in ten countries in Europe using a structured questionnaire coupled
with various sampling methods. Here we present the findings from the Italian population.
Methods: Questionnaires were distributed to a stratified sample (N = 3500) of the adult (18–65 years) inhabitants of
Pavia province (1.05 % of the general population), randomly selected in cooperation with the local health service.
Questions included demographic and diagnostic enquries, and assessment of various aspects of impact and
health-care utilisation.
Results: Altogether 500 questionnaires were returned of which 487 were adequately completed for analysis (58 %
female, 42 % male). Among these, gender-adjusted lifetime prevalence of headache was 82.5 %, higher in females
than in males (91.2 % vs 72.4 %; p < 0.0001). Gender-adjusted 1-year prevalence was 74.2 % (females 87.7 %, males
61.1 %; p < 0.0001). The most prevalent headache type was migraine (gender-adjusted 1-year prevalence 42.9 %;
females 54.6 %, males 32.5 %; p < 0.0001), followed by TTH (28.6 %; no gender-related difference); all causes of
headache on ≥15 days/month were reported by 7.0 % of participants (females 10.6 %, males 2.0 %; p = 0.0002), of
whom 2.1 %,, all female (p = 0.0064) concomitantly overused acute medications (therefore probable MOH). Only
16.6 % of responders reporting headache had received a diagnosis from a doctor, and very few (2.4 %) were taking
preventative medications. Headache had negative impacts on different aspects of life: education, career and
earnings, family and social life. Each person with headache had lost, on average, 2.3 days from paid work and
2.4 days from household work, and missed social occasions on 1.2 days, in the preceding 3 months. An increasing
gradient for impact was observed from episodic to chronic forms of headache.
Conclusions: Our study reveals that in Italy, as in other countries, migraine, TTH and MOH are highly prevalent and
are associated with significant personal impact. These findings have important implications for health policy in Italy.
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Background
The World Health Organization identified headache
disorders as a public health priority in 2000 [1, 2]. On a
clinical level it has long been evident that primary head-
ache disorders, migraine and tension-type headache
(TTH) in particular, are often lifelong illnesses which, as
well as directly causing pain and disability, hinder family
and social relationships and impoverish quality of life.
Epidemiologically, a large number of studies provide evi-
dence that headache among populations is ubiquitous
and common [3], although many published studies prior
to the last decade focused on prevalence to the exclusion
of burden. The Global Campaign against Headache, con-
ducted by Lifting The Burden (LTB) in official relations
with the World Health Organization [4–6], set out to fill
this knowledge gap as its first priority, developing stan-
dardised methodology [7]. Population-based studies in
China [8], India [9] and Russia [10] in time for inclusion
in the Global Burden of Disease study 2010 (GBD2010)
[11] saw migraine recognised as the seventh cause of
disability worldwide, with a mean estimated global
prevalence of 14.7 % among adults [11, 12]. More re-
cently, the Global Burden of Disease Study 2013
(GBD2013), with better information still, reported mi-
graine as the sixth highest cause of disability worldwide
[13]. Importantly, GBD2013 included MOH for the first
time, and it entered the top twenty causes of disability.
TTH was considered relatively non-disabling but, col-
lectively, headache disorders ranked third [14].
In Europe, meanwhile, although many studies had re-
ported migraine prevalence, there were still knowledge
gaps regarding TTH and MOH, and for all headache
types there were few published reports of burden. The
Eurolight Project commenced in May 2007, using modi-
fied cluster-sampling in 10 countries of Europe to assess
the impact of headache [15]. Multiple scientific and lay
organisations collaborated with headache experts in these
countries, and not all were able to draw population-based
samples. The survey used the same structured question-
naire in each country, translated into the local languages,
with diagnostic questions based on ICHD-II [16] taken
from the HARDSHIP questionnaire [17]. Eurolight gath-
ered analysable data from 8271 adult participants, with
participation-rates between 10.6 and 58.8 % and detectable
moderate interest-bias. Gender-adjusted 1-year prevalence
of any headache was 78.6 %, of migraine 35.3 %, of TTH
38.2 %, of headache on ≥15 days/month 7.2 %, of probable
MOH 3.1 % [18]. Personal impact was high, with a gradi-
ent of probable MOH>migraine > TTH, and generally
higher among females than males. Particularly notable
were the proportions of lost useful time: 17.7 % of males
and 28.0 % of females with migraine lost >10 % of days;
44.7 % of males and 53.7 % of females with probable
MOH lost >20 %. The conclusions of Eurolight were:
“The common headache disorders have very high personal
impact in the EU, with important implications for health
policy” [18].
The situation in Italy is that, Eurolight apart, few
data are available from the scientific literature regard-
ing the general population. Moreover, most published
studies have limitations: they were restricted to seg-
ments of the general population (the elderly [19, 20]
or adolescents [21]) or to selected types of headache
(eg, cluster headache [22]); or they were carried out
before the publication of ICHD-I [23]; or they did
not assess the impact of headache. Recently, however,
two surveys of the adult general population of Parma
based on door-to-door interviews reported a 1-year
prevalence of definite migraine of 24.7 % [24] and of
TTH of 19.4 % [25]. The finding for migraine is in
line with that of Eurolight (22.2 %) for Europe gener-
ally [18], and indicative of a major public-health
concern with substantial implications for health-care
policy, planning and resource-allocation. Here we
present the findings of Eurolight for the Italian popu-
lation in order to add to the knowledge on which
that policy might be based in Italy.
Methods
Ethics
The National Ethics Committee of Luxembourg gave
overall approval of the protocol. Further approvals in
Italy were obtained from the Ethics Committee of the
National Neurological Institute C. Mondino.
Data protection approval was similarly obtained cen-
trally in Luxembourg, and data were held in compliance
with national and European privacy laws.
Prospective participants received a written information
sheet explaining the project and enquiry, and their
purpose.
Study design
The detailed methods of the Eurolight Project have been
published elsewhere [15]. It was a cross-sectional survey
of randomly-selected adults aged 18–65 years, using a
structured questionnaire.
Sampling
In Italy, the questionnaire was distributed to a represen-
tative sample of the general population living in Pavia
province in Lombardy region, Northern Italy (330,000
inhabitants, as reported in 2008 by the local registry of-
fice), in collaboration with Alleanza Cefalalgici - CIRNA
Foundation Onlus. Random urban (70 %) and rural
(30 %) samples were drawn from this population using
listings supplied by Azienda Sanitaria Locale (ASL) of
Pavia, stratified with regard to gender (M:F ratio 1:1),
age (in the range 18–65 years) and education.
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The sample was 3500 individuals (1.05 % of the gen-
eral population). Questionnaires and supporting docu-
ments were distributed by post to each of these, in a
parcel that also contained information about the study
and its objective, the informed-consent form to be
signed, instructions on how to complete the question-
naire and a prepaid envelope addressed to ASL for
returning the documents. No reminders were sent to
those who did not respond.
Questionnaire
The development, content and validation of the struc-
tured questionnaire have been previously described [26].
The original English version was translated into Italian
following LTB’s standardised translation protocol for lay
documents [27].
Demographic questions were followed by neutral
screening questions for headache (“Have you ever had a
headache?” and “Have you had a headache during the
last year?”) and, in those screening positively, by
headache-diagnostic questions based on ICHD-II and
several question sets addressing impact. The last in-
cluded questions enquiring into past use of the health
system and medications, the HALT questionnaire [28]
and two questions (How would you rate your quality of
life? and How satisfied are you with your ability to per-
form your daily living activities?) from WHOQoL-8 [29].
Diagnosis
Only one headache type (the most bothersome when
there was more than one identified) was diagnosed in
each participant. According to the algorithm used to
convert responses to diagnoses, headache occurring on
≥15 days/month was first set aside from episodic head-
ache, and diagnosed according to reported medication
consumption either as probable MOH (pMOH) or other
headache on ≥15 days/month. Among episodic head-
aches, definite migraine criteria were first applied, then
those of definite TTH, which trumped probable mi-
graine. After probable TTH, a small minority of head-
aches were unclassifiable. For purposes of analysis,
definite and probable migraine were considered together
as all-migraine, as were definite and probable TTH as
all-TTH.
Non-participants
We anticipated a low participation rate because of the
means of engagement (by post). We were concerned that
questionnaires were more likely to be completed and
returned by those most affected by headache (interest
bias). These considerations suggested our responding
sample would not be representative of the initial sample.
Therefore, a study of non-participants was conducted
by asking (by means of advertisements in the local
newspapers) those who had received the questionnaire
but not returned it to complete another much shorter
questionnaire published on the website of CIRNA
Foundation (www.cefalea.it). The short questionnaire
asked about occurrence and frequency of headache
during the last year and headache features to identify
probable migraine (using a migraine screening instru-
ment [30]).
Statistics
Categorical variables were described in terms of frequency
(n) and proportions (%, with 95 % confidence intervals
[CIs] where appropriate), continuous variables in terms of
means and standard deviations (SDs).
Analyses were done with the SAS software (version
9.1.3, SAS Inc., Cary, NC, USA), using the Chi squared
test. We considered a P value of <0.05 as statistically
significant.
Results
We received 500 questionnaires (participation rate
14.3 %), of which 487 were complete and usable for
analysis (males 203 [41.7 %], females 284 [58.3 %];
mean age 43.4 ± 12.6 years). All age groups were
similarly represented except those aged 25–29 (under-
represented by about 45 %) and those aged 40–44
(overrepresented by about 50 %). Almost all partici-
pants (98.0 %) were native Italian speakers. A large
majority (92.1 %) were living with a partner and two
thirds (67.9 %) were employed.
Headache prevalence
Of the 487 in the primary sample, 406 (83.4 %) re-
ported any headache at some time in their lives.
There was a gender-related difference: females
91.2 % (95 % CI: 87.7–94.3), males 72.4 % (95 % CI:
65.8–78.2; p < 0.0001); therefore the gender-adjusted
lifetime prevalence of any headache was 82.5 %.
There was fluctuating variation with age, in the
range 86–97 %, between 18 and 49 years; reported
prevalence declined then, presumably as a factor of
recall, to 79.3 % in those aged 50–54, 69.0 % in
those aged 55–59 and 64.4 % in those >60 years.
Of the 487, 373 (76.6 %) reported headache also in the
last year, again with a gender difference: females 87.7 %
(95 % CI: 84.2–91.8), males 61.1 % (95 % CI: 54.3–67.7;
p < 0.0001). The gender-adjusted 1-year prevalence of
any headache was 74.2 %. Reported 1-year prevalence
was clearly age-related, rising to a peak of 96.7 % in the
age range 25–29 years, flattening at 86–89 % between 30
and 44 years, then declining steadily, and more rapidly,
after age 54 (Table 1).
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Type of headache
There were 144 participants (29.6 %) algorithmically di-
agnosed with definite migraine and another 77 (15.8 %)
with probable migraine. The reported 1-year prevalence
of all-migraine was 45.5 % (95 % CI: 38.9–52.1 %). This
was the most prevalent headache type. Migraine was
more prevalent among females (54.6 %) than among
males (32.5 %; p < 0.0001). The gender-adjusted preva-
lence of migraine in the participating sample was there-
fore 42.9 %.
There were 119 participants (24.5 %) with definite
TTH and 20 (4.1 %) with probable TTH. The esti-
mated 1-year prevalence of all-TTH was 28.6 % (95 %
CI: 21.1–36.1 %). No gender-related difference was
observed in the prevalence of TTH (females 28.9 %;
males 28.1 %).
Headache on ≥15 days/month was reported by 34
participants (7.0 % [95 % CI: 5.0–9.6 %]). This was
very strongly gender-related, since 30 were females;
thus the prevalence (based on 1 month’s reporting) of
headache on ≥15 days/month was 10.6 % (95 % CI:
7.5–14.7 %) in females and 2.0 % (95 % CI: 0.6–5.1 %) in
males (p = 0.0002). Among this group were 10 (2.1 %
[95 % CI: 1.0–3.8 %]) with pMOH, all of whom were
female (p = 0.0064).
There were only four cases (0.8 %) of unclassified
headache.
Non-participant sample
A total of 202 questionnaires were completed by non-
participants (29.7 % male, 70.3 % female). Of these,
84.7 % reported headache at some time in their lives
(not different from the main sample), but only 38.1 %
(95 % CI: 31.7–45.0 %) had experienced headache in the
past year, far fewer than (in fact half ) the 76.6 % (95 %
CI: 72.6–80.1 %) of the main sample (p < 0.0001). Based
on the screening instrument [30], the prevalence of
migraine (deemed to be all probable) was 19.8 % (95 %
CI: 14.9–25.9 %), less than half that in the main sample
(p < 0.0001). The prevalence of all causes of headache




A majority (56.4 %) of those who reported headache in
the last year also reported ≥4 episodes of headache in
the preceding month (in effect, one or more headache
episode per week). Mean days of headache in the sample
was 4.8 ± 5.4. On the other hand, one fifth (20.3 %) re-
ported 0–1 attacks. There were 60 (12.3 %) reporting
headache on ≥10 days in the last month, including the
34 with headache on ≥15 days.
Since 76.6 % of the sample reported headache with
a mean frequency of 4.8 days/month, the probability
per person in the sample of having headache on any
particular day was 0.12 (0.766*[4.8/30]). Among the
sample of 487, 60 would therefore be expected to
have headache on any day. One of our questions was
“Did you have headache yesterday?”, to which 63
responded positively.
Productive time loss
The HALT questionnaire, incorporated into our enquiry,
captures headache-attributed lost time from paid work,
household work and social life [28]. The 373 participants
with headache in our sample, as a group, lost 857 days
from paid work in the preceding 3 months, a mean of
2.3 per person, extrapolating to 9.2 days/year or 4.0 % of
total working time (assuming 46 weeks worked per
year). There was evidence of a highly-disabled small
minority, with 20 people (4.1 % of the total sample)
reportedly losing >10 days and eight of these (1.6 %)
losing >30 days. From household work, 890 days (2.4
per person) were lost, and there were 461 lost social
occasions (1.2 per person).
Time losses at individual level were positively correlated
with frequency of attacks. For this reason they were great-
est in those with headache on ≥15 days/month. They were
otherwise dependent on diagnosis, being greater in mi-
graine than in TTH.
Impact on professional life
We asked a range of questions pertinent to career and
professional prospects, beginning with “Do you feel that
your headaches have interfered with your education?”
Only 27 (7.2 % [95 % CI: 4.9–10.4 %] of those reporting
headache) replied “yes”; specifically, 24 believed they had
done less well and three had given up early. Of the 27,
most (22) had migraine (10.0 % [95 % CI: 6.6–14.7 %]
of those with migraine) but three (30.0 % [95 % CI:
Table 1 Reported 1-year prevalence of any headache in
participating sample by age
Age
(years)
Proportion reporting headache in thelast year
n % (95 % CI)
18–25 41 78.8 (67.9–90.1)
25–29 29 96.7 (90.9–100)
30–34 41 89.1 (80.0–98.0)
35–39 44 86.3 (76.5–95.5)
40–44 71 88.8 (82.1–95.9)
45–49 42 79.2 (68.0–90.0)
50–54 41 70.7 (59.3–82.7)
55–59 35 60.3 (47.4–72.6)
60–65 29 49.2 (36.2–61.8)
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10.3–60.8 %]) had pMOH. Almost the same numbers be-
lieved their headaches had hindered their professional ca-
reers: in fact, predictably, the same 27 people replied “yes”
to this question also, but so did three more with pMOH,
to make an overall total of 30 (8.0 % [95 % CI: 5.7–
11.3 %]) including six (60.0 % [95 % CI: 31.2–83.3 %]) of
those with pMOH. Of these 30, 20 (5.4 % [95 % CI: 3.5–
8.2 %]) believed they had done less well, five (1.3 % [95 %
CI: 0.5–3.2 %]) had taken an easier job and seven (1.9 %
[95 % CI: 0.8–3.9 %]) had required long-term sick-leave
(multiple responses were possible to this question). No
participant reported early retirement because of headache.
A smaller number (12 [3.2 %; 95 % CI: 1.8–5.6 %])
believed their headaches had limited their incomes,
most (9) of whom had migraine while two had
pMOH.
Related to employment and work prospects was the
question “Do you feel your headaches are understood by
your employer and work colleagues?” In all, 50 partici-
pants (13.4 % [95 % CI: 10.3–17.3 %] of those with head-
ache) felt not, including not very dissimilar proportions
with migraine (13.6 % [95 % CI: 9.0–18.0 %]) and TTH
(10.8 % [95 % CI: 5.6–16.0 %]) and three (30.0 % [95 %
CI: 10.3–60.8 %] with pMOH.
Impact on family life
One way in which headaches interfered with family life
was by causing social activities to be missed (reported
above). We also enquired into negative effects upon
family relationships, childcare, family planning and love
life, but our sample was not large enough to support a
worthwhile analysis of these.
We asked: “Do you feel your headaches are under-
stood by your family?” Only 31 participants (8.3 % [95 %
CI: 5.9–11.6 %] of those with headache) responded “no”,
spread through the diagnostic groups, and we did not
analyse these further.
Impact on quality of life
Most (340: 69.8 %) of the 487 participants considered
their quality of life good or very good, and there was lit-
tle difference between those with no headache (70.1 %),
migraine (69.7 %) or TTH (72.7 %). Of the 10 partici-
pants with pMOH, however, only two (20.0 % [95 % CI:
4.6–52.1 %]; P = 0.0019) reported good or very good
quality of life.
We asked “How satisfied are you with your ability to
perform your daily living activities?” [29]. Of the total
sample, 70.4 % were satisfied or very satisfied, as were
very similar proportions with migraine (70.1 % [95 % CI:
63.8–75.8 %]) or TTH (74.8 % [95 % CI: 67.0–81.3 %]).
Among those with pMOH, satisfaction was much lower
(10.0 % [95 % CI: 0.01–42.6 %]).
Use of health care
Despite the high prevalence of headache in our sample,
only 16.6 % of participants reporting headache had re-
ceived a diagnosis from a doctor. Only 36 (9.7 % of those
reporting headache) had consulted a primary-care phys-
ician in the last year; 18 (4.8 %) had reached a headache
specialist; three (0.8 %) had been seen in a hospital
emergency room.
The great majority (84.0 %) of those with headache
had used symptomatic drugs for headache attacks in
the last 30 days, whereas only 2.4 % were taking pre-
ventative medication. The use of preventative medi-
cation was higher among participants with headache
on ≥15 days/month, but numbers were too small to
analyse reliably.
Discussion
We need first to consider the limitations of this study,
because there were several. The Eurolight Project itself
“was a very large and organizationally complex study, in-
volving multiple collaborating partners (academic and
lay) in ten countries [making] pragmatic methodological
compromises in order to complete it” [18]. It had con-
siderable strengths: a questionnaire already used and val-
idated by LTB in many different countries, cultures and
translations (the HARDSHIP questionnaire [17]); neutral
screening questions expected to lead to better ascertain-
ment than questions incorporating degrees of frequency
or severity [7]; diagnoses made according to a standard
algorithm also developed and widely used by LTB [17].
Nevertheless, Eurolight could not undertake diagnostic
validation in each of the translations used, so diagnostic
accuracy was not directly assessed. This was one limita-
tion here. The modified cluster-sampling approach of
Eurolight, using different sampling methods in different
countries, was seen as a strength of the main project
[18], since it was not a primary purpose of Eurolight to
generate representative data at national level. For this,
its sampling methods were less suited, so this was a sec-
ond limitation here. The third key limitation was the
non-participation rate of 85.7 %.
With regard to diagnosis, we believe the instrument
was reliable in view of its successful use elsewhere [17],
and we draw attention as evidence of this to the ex-
pected gender differential in migraine but not TTH.
Nonetheless, we are circumspect about making compari-
sons between migraine and TTH, which were not the
main purpose of this report. Headache on ≥15 days/
month was diagnosed (as a group of disorders) simply
on the basis of reported frequency, and, among these,
pMOH on the basis additionally of reported medication
use. We see very clear differentials in impact between
the episodic headaches and pMOH. The key messages of
this report relate to headache disorders.
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For the Eurolight project we sampled from one area of
Italy: Pavia province in Lombardy region, Northern Italy,
an area of industry, high population density and (relative
to Italy as a whole) high gross domestic product (GDP).
It is not representative of the country. Nevertheless,
sampling, carefully stratified, was from the general popu-
lation across the area, urban and rural; unless there are
cultural, environmental or genetic factors varying across
Italy that greatly influence the prevalence or expression
of headache disorders, the findings from this area should
at least be indicative for Italy as a whole. The sample,
mostly of employed people living with partners, was
good for investigating the impact of headache on the dif-
ferent aspects of life.
Much more troublesome is the high non-participation
rate — not, of course, unusual in a postal survey. There
was clear evidence of interest-bias, as might be expected;
the non-participant survey recorded prevalences that
were less than half those reported by the primary re-
sponders. A special reason for interest bias might be
that, in Pavia, we have had a very active headache centre
for over 30 years; many who participated may have been
followed by the centre in the past, and responded be-
cause they were sensitive to the issue. However, it would
not be correct to assume that this smaller sample,
responding to a much shorter questionnaire, provided
more reliable data.
With these limitations of our own study in mind, we
review other available data. In Italy, as we noted, the epi-
demiology of headache disorders is not well established,
and data on impact are very few. One study only has
been performed on a sample representative of the gen-
eral population [31], but this predated and therefore
could not use accepted diagnostic criteria. It involved
the small independent Republic of San Marino, and ad-
ministered a questionnaire face-to-face to a random
sample of 1500 subjects over 7 years of age summoned
by mail. Of the 76.3 % who agreed to be interviewed,
528 (46.1 %) reported headache during the previous year.
One-year prevalence of migraine was estimated at 9.3 %
in males and 18 % in females. More recent but less
population-based was the sample of 71,588 patients
interviewed by 902 general practitioners (GPs) [32]. All
patients who visited the GPs for any reason during five
consecutive days of two different weeks were asked
whether they suffered from headache; if they did, the GP
completed a diagnostic questionnaire based on ICHD-I
[23]. The estimated prevalence of migraine in this sam-
ple was 11.6 % (5.0 % in males and 15.8 % in females).
Other epidemiological studies in Italy have focused
on selected groups. Prencipe et al [19], surveyed 1147
people aged ≥65 years in three rural villages in cen-
tral Italy, 72.6 % of whom completed the protocol,
including clinical evaluation by a neurologist and
diagnosis according to ICHD-I [23] (with minor mod-
ifications in order to classify patients with headache
on ≥15 days/month, then referred to as “chronic daily
headache” [CDH]). Estimated 1-year prevalence of mi-
graine was 11.0 %, of TTH 44.5 % and of CDH 4.4 %
(with one third of these being pMOH). The similar
study of 1031 residents aged ≥65 years of a rural
village in southern Italy found that 225 (21.8 %) suf-
fered from recurrent headaches (defined as ≥3 attacks
within the past 12 months) [20]. Estimated 1-year
prevalence of migraine was 4.6 %, of TTH 16 % and
of pMOH 1.3 %. Both migraine and TTH were sig-
nificantly more prevalent among females than males;
only migraine prevalence significantly decreased with
increasing age. Raieli et al surveyed 1445 students
aged 11–14 years, diagnosing migraine by question-
naire and neurological examination and using the cri-
teria of ICHD-I [23]. Prevalence of migraine without
aura was 2.35 %, of migraine with aura 0.62 %.
More recently, Ferrante and colleagues [24] collabo-
rated with GPs to survey the prevalence and clinical
features of primary headaches in an adult population
of the Emilia-Romagna region in Northern Italy. They
evaluated 904 subjects using face-to-face interviews
by a specialist of the Headache Centre of Parma. The
1-year adjusted prevalence of definite migraine (in-
cluding chronic migraine) was 24.7 % and of probable
migraine 5.1 %.
The emerging picture is far from clear. Ferrante’s study
indicates a prevalence of all-migraine of 29.8 %, about
one third lower than our gender-adjusted 42.9 % but
considerably higher than the 19.8 % of our non-
participant sample. While the mean global prevalence of
migraine was estimated at 14.7 % in GBD2010 [11], sev-
eral other LTB studies estimating the 1-year prevalence
of migraine have found values in the range 20–26 %: in
Russia 20.8 % [10]; in India 25.6 % [9]; in Zambia 22.9 %
[33]; in Pakistan 22.9 % [34]. Ferrante’s finding is not un-
reasonable in the light of these, and we would say it is
closer to the truth than ours, since we must recognise in
ours the effect of interest bias. Eurolight was more fo-
cused on impact than prevalence, and it is insights into
impact that this report is able to add.
As regards TTH, Ferrante et al [25] reported a crude
prevalence of 19.4 %, similar to the 21.2 % reported by
Vukovic in nearby Croatia [35], while our reported
prevalence of 28.6 % is closer to the 30.9 % observed by
Ayzenberg et al in Russia [10]. Our finding (as, indeed,
that of Ayzenberg et al, who used a similar question-
naire) was subject to systematic underestimation since
we diagnosed only one headache type (the most bother-
some) in any participant with more than one. The ample
variability in TTH prevalence that can be found in the
literature (from 5.1 to 74.0 % [36–38], is probably
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dependent on a multiplicity of reasons, but more on
variable methodological approaches and cultural differ-
ences in reporting the often mild and infrequent head-
ache of TTH than true differences between populations
due to geographical, demographic, racial, economic and
psychosocial factors. This consideration underscores the
need of national data for the correct implementation of
adequate health care policies.
We saw that more than half (56.4 %) of those report-
ing headache in the last year were experiencing one or
more headache episodes per week. One participant in
eight (12.3 %) reported headache on ≥10 days in the last
month. The frequencies reported generated an expect-
ation that 60 of the sample of 487 would have headache
on any one day. In fact, 63 reported headache yesterday,
strongly supporting the responses based on recall (and
validating the enquiry).
More than two thirds of our sample were employed.
Each person with headache lost, on average, 2.3 days
from paid work in the preceding 3 months, extrapolating
to 9.2 days/year or 4.0 % of total working time. Spread
between the entire sample of 487, this would represent a
huge 3.1 % loss to GDP. Much of this was attributable
to the highly-disabled small minority – the 20 people
(4.1 % of the sample) losing >10 days and, particularly,
the eight of these (1.6 %) losing >30 days. Even so, we
suspect this finding was also influenced by interest bias;
since losses at individual level were greater from mi-
graine than from TTH, we suggest a conservative down-
rating of the estimate by one third, in line with the
prevalence estimate of Ferrante et al [24] rather than
our own. The revised loss to GDP of 2.0 % still exceeds
estimates made by LTB for Russia (1.75 % [10]), China
(1.9 % [8]) and Zambia (1.9 %) [33]). It should be noted
that losses from household work were equally great, and
these are also economically important.
People with difficulties at work were not helped by
employers or colleagues who offered no understanding
(in 50 reported cases), perhaps unsurprisingly when they
bore the burden of the headache sufferer’s absenteeism.
At home, 31 felt a lack of understanding. Nonetheless,
most people with headache were not aware of negative
consequences on education, career and professional
prospects, family life or quality of life, although in each
of these domains there was a disaffected minority. The
consequences for the 27 (most with migraine) who
believed they had done less well at school, or given up
early, were potentially cumulative through a lifetime. So
were they for the 30 who believed their headaches had
hindered their careers, and the 12 who believed their
headaches had limited their incomes. Again, most had
migraine. Still the great majority of people with head-
ache – at least those with episodic headache – seemed
to get on with their lives. The two quality-of-life
questions showed no differences between those with no
headache, those with migraine and those with TTH, al-
though those with pMOH scored well below all others
on both questions.
Despite that 76.6 % of our sample reported headache
within the last year, only 16.6 % of these had a doctor’s
diagnosis and, in the last year, only 9.7 % had consulted a
primary-care physician and 4.8 % a headache specialist.
Here, interest bias is likely to mean that these numbers
are higher than the norm (ie, a better picture than reality).
There are many reasons for consultation-failure, including
patient inaction. Torelli et al [39] assessed disease percep-
tion among a sample of 904 subjects; of 387 (123 males,
264 females) who reported headache in the past year, only
one third perceived themselves as “headache sufferers”,
this perception being dependent on headache frequency
in females only. But, whatever its cause, the end-result of
health-care failure, so evident in our study with only 2.4 %
taking preventative medication despite that more than half
the sample reported ≥4 headache days/month, is unre-
lieved burden, including symptom burden, disability, pro-
ductive time losses and the inordinate losses to GDP.
Conclusions
Eurolight is not, generally, a source of reliable epidemio-
logical data [18], a point we emphasise. The data from Italy
were population-based, but from a selected area of the in-
dustrial north; furthermore, there was low participation.
Eurolight’s strength was its detailed enquiry into impact.
Taking other prevalence data into account, a fair picture
can be painted of headache in Italy. As in other countries,
headache disorders are highly prevalent and burdensome.
In Italy, the high impact on individuals is matched by high
economic burden; both are unmitigated by health-care fail-
ure. There is a highly-disabled small minority. Health pol-
icy in Italy must take note of these findings, of suggestions
that Italy fares worse than other countries, and of the
World Health Organization’s advice that effective treat-
ment of headache is desirable not only for its health bene-
fits but also because it is likely to be cost-saving [40].
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